Transdermal non-aqueous nanoemulgels for systemic delivery of aromatase inhibitor

Transdermal nanoemugels for systemic delivery of potent drugs like aromatase inhibitors letrozole and anastrozole are disclosed. The disclosed compositions may include gelling agent, surfactants, cosolvents, and oily components. The process of preparing the nanoemulgels is simple and the formation of nanoemulgels is spontaneous. Penetration enhancers are included in the compositions of the transdermal nanoemugels. The compositions have penetration power with emollient effects to the skin. The transdermal drug delivery system may be applied to skin in a single dose that produces pharmacologically effective blood concentration of the potent drug for one week or up to one month depending on the amount and thickness of the applied nanoemugels in the transdermal matrix patches.The nanoemulgels can be used for topical delivery of NSAID..

Medienart:

Patent

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Europäisches Patentamt - (2021) vom: 30. Nov. Zur Gesamtaufnahme - year:2021

Sprache:

Englisch

Beteiligte Personen:

SALLAM ASSAYED ALARABI NAUMAN [VerfasserIn]
YOUNES HUSAM M [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
B82Y: Specific uses or applications of nanostructures; me (...)
che
phy
tec

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2021-11-30, Last update posted on www.tib.eu: 2023-12-21, Last updated: 2023-12-29

Patentnummer:

US11185504

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA015565157